We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · June 16, 2022

ASCO 2022: KEYNOTE-716 Update Confirms Benefits of Adjuvant Pembrolizumab in Stage IIB/IIC Melanoma

Both recurrence-free and distant metastasis-free survival were better with pembrolizumab than placebo

PracticeUpdate Editorial Team

 

Further Reading